About SMS Lifesciences India Limited

SMS Lifesciences India Limited is a leading Active Pharmaceutical Ingredients (API) and bulk drugs manufacturer with operations across India and global markets. Incorporated post the demerger from SMS Pharmaceuticals, it operates state-of-the-art cGMP and WHO-compliant facilities at Hyderabad (Kazipally and Jeedimetla) with a combined installed capacity of approximately 800 KL geared towards manufacturing over 55 APIs covering 14 therapeutic segments. The company is renowned for key products such as Ranitidine and Famotidine and maintains a robust research and development centre recognised by the Department of Scientific and Industrial Research (DSIR) focused on process innovation, route synthesis, and analytical development.

In FY 2024–25, SMS Lifesciences reported revenue distribution with 58.53% domestic sales and 39.30% exports, serving over 75 countries globally including significant regulated markets accounting for nearly 88% of revenues. The company expanded its international regulatory credentials with successful USFDA audits at its Hyderabad unit and its subsidiary API facility in early 2025, each earning zero observations and reaffirming quality norms. SMS Lifesciences also continues to build capacity and diversify product lines with new APIs and backward integration pilots while incubating CRAMS and peptide-based Contract Research Organisation (CRO) capabilities.

Key Milestones of SMS Lifesciences India Limited

• 1990 – Company formation as a chemical API manufacturer, initially single product and location.
• Post-demerging from SMS Pharmaceuticals to establish a focused API business.
• 2010s – Expansion of multi-product manufacturing units with Asia’s largest single production block for Ibuprofen established at Visakhapatnam.
• 2024–25 – Acquisition of a majority stake (93%) in a subsidiary; successful USFDA and regulatory audits; launch of new APIs supported by enhanced R&D investment.

SMS Lifesciences India Limited Business Verticals and Geographic Presence

Business Verticals:

• Manufacturing and supply of APIs and Intermediates across diverse therapeutic areas including anti-ulcer, anti-migraine, anti-inflammatory, anti-migraine, anti-retroviral, anti-diabetic, anti-erectile dysfunction, among others.
• Diversification into CRAMS and peptide-based CRO services for global pharma clients.

Geographical Revenue Mix (FY 2024–25):

• Domestic Market: 58.53% revenue contribution.
• International Market: 39.30% from exports.
• Deemed Exports: 1.99%.
• Export Incentive: 0.18%.
• Regulated markets composed nearly 88% of global revenues, reflecting strong compliance.

SMS Lifesciences India Limited Key Management

• TVVSN Murthy – Managing Director
• T V Praveen – Executive Director
• Sudeepthi Gopineedi – Whole-time Director
• N. Rajendra Prasad – Chief Financial Officer
• Trupti Ranjan Mohanty – Company Secretary

Latest Updates on SMS Lifesciences India Limited

• Acquisition of 93% stake in a subsidiary effective November 1, 2024, consolidating the operational and regulatory footprint.
• Conversion of 40 lakh share warrants into equity shares at a premium of Rs 126 per share to Promoters/Promoter Group.
• Commissioning of strategic backward integration projects and additions of six new APIs, with R&D continually funded at 2.4% of sales.
• Successful USFDA audits at the Hyderabad and subsidiary API units with zero observations, confirming robust quality systems.
• Preparations underway for ANVISA inspection (Brazil) to augment Latin American market access.
• Planned API capacity enhancements and production line additions targeted for FY 2026–27.
• Active expansion of contract manufacturing projects to diversify customer base and improve global collaborations.
• Promoter shareholding increased to 71.41% as of March 31, 2025.
• Investor outreach campaign “Saksham Niveshak – 100 Days Campaign” launched to facilitate KYC updation and dividend claims.